Harry J. Leonhardt
2015 - Halozyme Therapeutics
In 2015, Harry J. Leonhardt earned a total compensation of $2.9M as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Halozyme Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $145,000 |
|---|---|
| Option Awards | $2,070,717 |
| Salary | $262,163 |
| Stock Awards | $429,825 |
| Other | $8,383 |
| Total | $2,916,088 |
Leonhardt received $2.1M in option awards, accounting for 71% of the total pay in 2015.
Leonhardt also received $145K in non-equity incentive plan, $262.2K in salary, $429.8K in stock awards and $8.4K in other compensation.
Rankings
In 2015, Harry J. Leonhardt's compensation ranked 3,274th out of 13,638 executives tracked by ExecPay. In other words, Leonhardt earned more than 76.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,274 out of 13,638 | 76th |
Division Manufacturing | 1,186 out of 5,187 | 77th |
Major group Chemicals And Allied Products | 432 out of 1,857 | 77th |
Industry group Drugs | 342 out of 1,531 | 78th |
Industry Biological Products, Except Diagnostic Substances | 57 out of 260 | 78th |
Source: SEC filing on March 24, 2017.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2015.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019